Damon Runyon Researchers

Meet Our Scientists
Matthew G. Oser, MD, PhD

Although small cell lung cancer (SCLC) is initially highly responsive to chemotherapy, the disease recurs in nearly all patients in less than a year. There are currently no approved targeted therapies for when the cancer returns. Previous studies have demonstrated that SCLCs require sustained neuroendocrine differentiation for survival, suggesting that targeting this process could be a good therapeutic strategy. Dr. Oser will use SCLC patient-derived xenograft models and a novel SCLC genetically engineered mouse model to identify new enzymes required for neuroendocrine differentiation and to develop targeted therapies that can block this process. He aims to identify molecular targets that could be developed into new lasting therapies for SCLC patients. Dr. Oser works under the mentorship of William G. Kaelin Jr., MD, at the Dana-Farber Cancer Institute, Boston.

Project title: "Targeting neuroendocrine differentiation as a novel therapeutic strategy for small cell lung cancer"
Institution: Dana-Farber Cancer Institute
Award Program: Clinical Investigator
Sponsor(s) / Mentor(s): William G. Kaelin, Jr., MD
Cancer Type: Lung
Research Area: Experimental Therapeutics